|
Hologic posts Q2 results, $3.7B deal to buy Gen-Probe
 April 30, 2012 -- Women's imaging vendor Hologic swung to a net loss for the company's second quarter, despite 7% growth in the firm's revenues for the period. Separately, Hologic announced a $3.7 billion deal to buy diagnostics firm Gen-Probe.
To view the remainder of this article, and other exclusive content, you must first sign-in or register using the options below.
(Helptag:PaywallArticleLoginMessage)
| |
|
|
New AuntMinnie.com Members
|
Becoming a Member is FREE!
|
Real-time radiology-specific news
Case of the Day and Teaching Files
Focused topics digital communities
Lively, discussion groups
Medical imaging bookstore
SalaryScan
Job Boards
OnLine CMe/CE
Bookstore, market reports, more …
Conference Calendar
User-controlled eNewsletters
… registration is FREE and easy!
|
| |
|
For the quarter, Hologic posted revenues of $471.2 million, up 7.4% compared to revenues of $438.7 million in the same period the year before. Revenues in the company's Breast Health segment increased to $218.6 million, up 6.2% compared to $205.9 million in the corresponding quarter last year.
The company's net loss for the period was $40.3 million, compared with net income of $82.4 in the second quarter of 2011.
On April 30, Hologic announced a deal worth $3.7 billion to acquire Gen-Probe, a developer of molecular diagnostics products and services. Gen-Probe makes products such as blood tests for detecting sexually transmitted diseases and the West Nile virus.
Hologic expects the deal to be accretive to earnings, with the combined company having annual revenues of $2.4 billion. The acquisition is expected to close in the second half of 2012. | |
|